Developer docs
API playgroundTry for free, no card

Search company profiles

Sapien Biosciences

Full company profile

uuid0059hdw

Namestring
Sapien Biosciences
Legal namestring
Sapien Biosciences
Websiteurl
sapienbio.co.in
Company typeenum
Private
Founded yearint
2012
Descriptiontext

Sapien Biosciences is a Hyderabad-based joint venture between Apollo Hospitals and Saarum Innovations, founded in 2012, operating Asia's largest commercial tumor tissue biobank with 200,000 unique patients, 2,045,000 samples, and 150 unique diseases covered. The company is structured around an ethically consented, anonymized human sample repository linked to associated clinical, pathological, and diagnostic data, and uses this asset to power a portfolio of translational platforms—OncoBloc (FFPE collections), OncoPrime (patient-derived live cancer cells), MetBlock (EMT-based metastasis model), TruCell (patient/normal cells), and TruScreen (functional drug-efficacy assays)—alongside companion diagnostic products including the myPlatelet combination genetic/functional platelet test, a 43-gene HRR NGS panel for ovarian cancer, and BRCA1/2 testing.

The company's commercial offering spans biobank access, drug-discovery partnerships with global pharmaceutical and biotech firms, in-house and co-developed companion diagnostics, immunohistochemistry and digital pathology services at 40X whole-slide resolution, and immuno-oncology cell assays including 2D/3D spheroid and DC-MLR models. Revenue mechanics combine subscription-style biobank access, licensing/royalty arrangements on diagnostic IP, professional services for collaborative research, and per-test fees for diagnostics such as myPlatelet. Go-to-market is enterprise B2B, distributed through direct sales to pharma/biotech and academic institutions, with Apollo Hospitals functioning as both a strategic JV parent and the primary distribution channel for diagnostic deployment across its hospital network.

Sapien serves three primary customer segments—pharmaceutical and biotechnology companies requiring human samples and patient-derived models for preclinical and translational work, academic and research institutions conducting cancer and life sciences research, and healthcare providers/hospitals implementing personalized medicine diagnostics. The company holds no external venture or private equity funding disclosed in the source material, and is operated by founders Jugnu Jain (CSO), Sreevatsa Natarajan (CEO), and Prithi Rajan (Executive Director) with combined 60+ years of R&D experience.

Short descriptiontext

Sapien Biosciences is a Hyderabad-based joint venture between Apollo Hospitals and Saarum Innovations operating Asia's largest commercial biobank of 200,000 patients, providing companion diagnostics, patient-derived tumor models, and phenotypic drug discovery services to pharma, biotech, and academic clients.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersHyderabad, India
HQ citystring
Hyderabad
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
biobanking services, companion diagnostics, phenotypic drug discovery, translational research, patient-derived cell models
Industry5 codes
PRIMARYHLACAMAG
Biobank & Biospecimen Management LIMS
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
SECONDARYHLAGAJAF
Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAAAK
Real-World Evidence (RWE), HEOR & Epidemiology CROs
NAICS code3 codes
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
SIC code3 codes
  • Services-Medical Laboratories8071
  • Services-Commercial Physical & Biological Research8731
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Biobanking & Translational Research Services
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Biobanking Services
TypeSubscription Recurring
Description

Providing ethically consented human samples with associated medical and diagnostic data to pharmaceutical companies, biotech firms, and academic researchers for drug discovery and biomarker validation.

sapienbio.co.in
2Diagnostic Development
TypeLicensing Royalties
Description

Developing and commercializing novel diagnostic tests including companion diagnostics and personalized medicine applications, either in-house or in collaboration with partner institutions.

sapienbio.co.in
3Drug Discovery Partnerships
TypeProfessional Services
Description

Partnering with global pharmaceutical and biotech companies to study disease epidemiology, validate new diagnostics, identify drug targets, and evaluate new drugs using proprietary biobank resources.

sapienbio.co.in
4myPlatelet Test
TypeTransaction Fee
Description

Commercial sale of proprietary combination genetic and functional platelet function test for cardiology patients undergoing PCI-stent procedures.

sapienbio.co.in
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 6 records shown
1OncoBloc
Description

Fixed and frozen FFPE sample collections for cancer research.

sapienbio.co.in
+5 more records
Core offering1 text field

Sapien Biosciences operates one of Asia's largest commercial biobanks with 200,000 unique patients, 2,045,000 samples, and 150 unique diseases covered, providing ethically consented, anonymized human tissue samples with associated clinical data. The company offers proprietary translational platforms (OncoBloc FFPE collections, OncoPrime patient-derived live cancer cells, MetBlock metastasis EMT model, TruCell, TruScreen) and companion diagnostic tests (myPLATELET pharmacogenomic platelet test, HRR NGS panel, BRCA1/2 testing) for pharmaceutical companies, biotech firms, academic researchers, and healthcare providers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Patient-derived models contributing to Phase III clinical development program
+2 more records
Product overview1 text field

Sapien Biosciences is a biobank-led companion diagnostics and phenotypic drug discovery company offering a comprehensive portfolio of products and services. The core offering centers on Asia's largest commercial biobank with over 200,000 patients and 2 million+ samples. This biobank powers multiple translational platforms including OncoBloc (FFPE collections), OncoPrime (patient-derived live cancer cells), MetBlock (metastasis EMT model), TruCell (patient/normal cells), and TruScreen (functional assays). The company provides companion diagnostic services including myPLATELET (pharmacogenomic platelet function test), HRR NGS panel testing for PARP inhibitor guidance, and BRCA1/2 testing. Additional services include IHC staining with digital pathology and cell-based immuno-oncology assays for drug efficacy testing.

Product and service10 records
1OncoBloc
CategoryTranslational Platform
2OncoPrime
CategoryTranslational Platform
3MetBlock
CategoryTranslational Platform
4TruCell
CategoryTranslational Platform
5TruScreen
CategoryTranslational Platform
6myPLATELET
CategoryCompanion Diagnostic
7HRR NGS Panel (43-gene)
CategoryCompanion Diagnostic
8Biobank Services
CategoryBiobanking Service
9IHC Staining & Digital Pathology Services
CategoryDiagnostic Service
10Cell Assays for Immuno-Oncology
CategoryDrug Discovery Service
Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Joint venture partnership creating a world-class biobank and personalized medicine company. Sapien has exclusive access to the entire Apollo network for biobanking needs. Alliance allows Sapien to front-end Apollo's personalized medicine initiatives, bringing novel cutting-edge diagnostics to Apollo either independently or in collaboration with global institutions.

2Saarum Innovations
Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Co-founding partner providing cutting-edge life sciences research expertise. The Saarum team manages Sapien operations with over 60 years of combined global R&D experience in cell and molecular biology and drug and biomarker discovery.

sapienbio.co.in
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration on drug development efforts using Sapien's patient-derived models and NAMs. Contribution to Aveta's therapeutic program advancing toward Phase III clinical development, demonstrating meaningful translational insights for cancer patients.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration with Dr. Joglekar's group at Boston University Questrom School of Business to perform cost-benefit analysis of treatment paradigms in PCI-stent patients using Sapien's cardiac database of approximately 800 patients. Research expected to be published and pave way for additional studies.

Strategic tierMinorTypeGTM or Marketing Partner
Description

FABA-US Chapter webinar collaboration featuring Sapien's biobank capabilities. Dr. Jugnu Jain presented on human patient samples and clinical data at FABA-US monthly webinar series.

6Dr. PC Rath (Apollo Hospitals)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Leading cardiologist collaborating with Sapien on cardiac patient database collation and research on anti-platelet therapy optimization for PCI-stent patients.

sapienbio.co.in
7Dr. PK Sahoo (Apollo Hospitals)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Cardiologist collaborating on cardiac research and myPlatelet test utilization for personalized anti-platelet therapy in PCI-stent patients.

sapienbio.co.in
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Collaboration with Dr. A Yerramilli at SV College of Pharmacy for cardiac patient research and data analysis.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Mentioned in context of partnership discussions and industry collaboration for biobanking and life sciences ecosystem development.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic collaboration for glioma patient-derived 3D cultures research presented at Regional Young Investigator Meeting.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeRegional player
Description

India-headquartered genomics and translational research company offering NGS, biomarker, and clinical genomics services. Regional peer with overlapping India-population genetics focus and pharma/biotech diagnostics service offering.

TypeEmerging player
Description

Provider of human cell-based products, iPSC-derived cells, and biobanking services for drug discovery. Overlaps with Sapien's TruCell patient-derived cell platform and drug discovery service line.

TypeDirect peer
Description

Global human biospecimen supplier specializing in oncology and disease-state tissue with annotated clinical data. Comparable to Sapien's translational biobank services for pharma clients.

TypeDirect peer
Description

Specialized oncology biobank and translational CRO providing fresh-frozen and FFPE tumor tissue with clinical data, directly comparable to Sapien's OncoBloc and OncoPrime offerings.

TypeBroad incumbent
Description

Large established sample storage, biobanking, and life-science services provider with global footprint. Overlaps with Sapien's biobank services but operates at much broader scale and across many therapeutic areas.

TypeDirect peer
Description

Commercial provider of human tissue, biofluid, and cell specimens with associated data for research and diagnostic development. Direct peer in the biospecimen catalog business.

TypeRegional player
Description

India-based genomics, bioinformatics, and clinical diagnostics provider serving hospitals and pharma. Comparable on India footprint and clinical genomics/multi-omics services, partially overlapping with Sapien's HRR NGS panel and diagnostic development work.

TypeDirect peer
Description

One of the world's largest commercial biospecimen providers offering ethically sourced human samples and associated data to pharma/biotech. Sapien is a direct peer in the commercial biobank/cryobank space but with a narrower oncology and India focus.

TypeBroad incumbent
Description

Global life science products and services company offering biorepository and biospecimen solutions. A broad incumbent in the lab-services and biospecimen value chain that competes for similar pharma procurement budgets.

10Molecular Diagnostics (MolDx) Labs / Agilent Dako
TypeBroad incumbent
Description

Incumbent companion diagnostics and IHC/pharmDx providers such as Agilent Dako offering CDx development and IHC assays. Overlaps with Sapien's HRR NGS panel, myPlatelet, and IHC staining services in the precision medicine/CDx value chain.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature10 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Sapien Biosciences

Biobanking & Translational Research Servicessapienbio.co.in

Sapien Biosciences is a Hyderabad-based joint venture between Apollo Hospitals and Saarum Innovations operating Asia's largest commercial biobank of 200,000 patients, providing companion diagnostics, patient-derived tumor models, and phenotypic drug discovery services to pharma, biotech, and academic clients.

What Sapien Biosciences does

Sapien Biosciences is a Hyderabad-based joint venture between Apollo Hospitals and Saarum Innovations, founded in 2012, operating Asia's largest commercial tumor tissue biobank with 200,000 unique patients, 2,045,000 samples, and 150 unique diseases covered. The company is structured around an ethically consented, anonymized human sample repository linked to associated clinical, pathological, and diagnostic data, and uses this asset to power a portfolio of translational platforms—OncoBloc (FFPE collections), OncoPrime (patient-derived live cancer cells), MetBlock (EMT-based metastasis model), TruCell (patient/normal cells), and TruScreen (functional drug-efficacy assays)—alongside companion diagnostic products including the myPlatelet combination genetic/functional platelet test, a 43-gene HRR NGS panel for ovarian cancer, and BRCA1/2 testing.

The company's commercial offering spans biobank access, drug-discovery partnerships with global pharmaceutical and biotech firms, in-house and co-developed companion diagnostics, immunohistochemistry and digital pathology services at 40X whole-slide resolution, and immuno-oncology cell assays including 2D/3D spheroid and DC-MLR models. Revenue mechanics combine subscription-style biobank access, licensing/royalty arrangements on diagnostic IP, professional services for collaborative research, and per-test fees for diagnostics such as myPlatelet. Go-to-market is enterprise B2B, distributed through direct sales to pharma/biotech and academic institutions, with Apollo Hospitals functioning as both a strategic JV parent and the primary distribution channel for diagnostic deployment across its hospital network.

Sapien serves three primary customer segments—pharmaceutical and biotechnology companies requiring human samples and patient-derived models for preclinical and translational work, academic and research institutions conducting cancer and life sciences research, and healthcare providers/hospitals implementing personalized medicine diagnostics. The company holds no external venture or private equity funding disclosed in the source material, and is operated by founders Jugnu Jain (CSO), Sreevatsa Natarajan (CEO), and Prithi Rajan (Executive Director) with combined 60+ years of R&D experience.

Sapien Biosciences firmographics

Firmographics
Name
Sapien Biosciences
Legal name
Sapien Biosciences
Website
https://sapienbio.co.in
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
51–100 employees
Short description
Sapien Biosciences is a Hyderabad-based joint venture between Apollo Hospitals and Saarum Innovations operating Asia's largest commercial biobank of 200,000 patients, providing companion diagnostics, patient-derived tumor models, and phenotypic drug discovery services to pharma, biotech, and academic clients.
Ownership category
akta.pro rank

Sapien Biosciences industry classification

Industry
Product category
Biobanking & Translational Research Services
NAICS
Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
SIC
Services-Medical Laboratories (8071), Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLACAMAG
Biobank & Biospecimen Management LIMS
Healthcare & Life Sciences/Digital Health & Health IT/Laboratory Information Systems (LIS/LIMS) & Pathology Informatics
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAH
Cell-Based & Potency Assays (Bioassays)
SECONDARYHLAGAJAF
Clinical & Translational Informatics (Clinical Data Integration/Real-World Data for R&D)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGAAAK
Real-World Evidence (RWE), HEOR & Epidemiology CROs

Keywords

  • Biobanking services
  • Companion diagnostics
  • Phenotypic drug discovery
  • Translational research
  • Patient-derived cell models

Where Sapien Biosciences is headquartered

Location

Headquarters

HQ city
Hyderabad
HQ country
India
HQ region
Asia

Offices1 record

Markets served

Sapien Biosciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain

Revenue model

  1. Biobanking Services: Providing ethically consented human samples with associated medical and diagnostic data to pharmaceutical companies, biotech firms, and academic researchers for drug discovery and biomarker validation.
  2. Diagnostic Development: Developing and commercializing novel diagnostic tests including companion diagnostics and personalized medicine applications, either in-house or in collaboration with partner institutions.
  3. Drug Discovery Partnerships: Partnering with global pharmaceutical and biotech companies to study disease epidemiology, validate new diagnostics, identify drug targets, and evaluate new drugs using proprietary biobank resources.
  4. myPlatelet Test: Commercial sale of proprietary combination genetic and functional platelet function test for cardiology patients undergoing PCI-stent procedures.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels8 records

Sapien Biosciences product offering

Product offering

Core offering

Sapien Biosciences operates one of Asia's largest commercial biobanks with 200,000 unique patients, 2,045,000 samples, and 150 unique diseases covered, providing ethically consented, anonymized human tissue samples with associated clinical data. The company offers proprietary translational platforms (OncoBloc FFPE collections, OncoPrime patient-derived live cancer cells, MetBlock metastasis EMT model, TruCell, TruScreen) and companion diagnostic tests (myPLATELET pharmacogenomic platelet test, HRR NGS panel, BRCA1/2 testing) for pharmaceutical companies, biotech firms, academic researchers, and healthcare providers.

Product overview

Sapien Biosciences is a biobank-led companion diagnostics and phenotypic drug discovery company offering a comprehensive portfolio of products and services. The core offering centers on Asia's largest commercial biobank with over 200,000 patients and 2 million+ samples. This biobank powers multiple translational platforms including OncoBloc (FFPE collections), OncoPrime (patient-derived live cancer cells), MetBlock (metastasis EMT model), TruCell (patient/normal cells), and TruScreen (functional assays). The company provides companion diagnostic services including myPLATELET (pharmacogenomic platelet function test), HRR NGS panel testing for PARP inhibitor guidance, and BRCA1/2 testing. Additional services include IHC staining with digital pathology and cell-based immuno-oncology assays for drug efficacy testing.

Differentiator

Problem solved

Functional benefit

Brands

  • OncoBloc: Fixed and frozen FFPE sample collections for cancer research.
  • OncoPrime
  • MetBlock
  • TruCell
  • TruScreen
  • myPLATELET

Products and services

  • OncoBloc
  • OncoPrime
  • MetBlock
  • TruCell
  • TruScreen
  • myPLATELET
  • HRR NGS Panel (43-gene)
  • Biobank Services
  • IHC Staining & Digital Pathology Services
  • Cell Assays for Immuno-Oncology

Quantifiable outcome

  • Patient-derived models contributing to Phase III clinical development program
  • +2 more outcomes

Companies that use Sapien Biosciences

Customer profile

Named customers6 records

Segments3 records

Ideal customer profiles3 records

Sapien Biosciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature10 records

Sapien Biosciences partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered flagship, core and minor.

  • Apollo HospitalsflagshipStrategic or Co-development PartnerJoint venture partnership creating a world-class biobank and personalized medicine company. Sapien has exclusive access to the entire Apollo network for biobanking needs. Alliance allows Sapien to front-end Apollo's personalized medicine initiatives, bringing novel cutting-edge diagnostics to Apollo either independently or in collaboration with global institutions.
  • Saarum InnovationsflagshipStrategic or Co-development PartnerCo-founding partner providing cutting-edge life sciences research expertise. The Saarum team manages Sapien operations with over 60 years of combined global R&D experience in cell and molecular biology and drug and biomarker discovery.
  • Aveta BiomicscoreStrategic or Co-development PartnerCollaboration on drug development efforts using Sapien's patient-derived models and NAMs. Contribution to Aveta's therapeutic program advancing toward Phase III clinical development, demonstrating meaningful translational insights for cancer patients.
  • Boston UniversitycoreStrategic or Co-development PartnerCollaboration with Dr. Joglekar's group at Boston University Questrom School of Business to perform cost-benefit analysis of treatment paradigms in PCI-stent patients using Sapien's cardiac database of approximately 800 patients. Research expected to be published and pave way for additional studies.
  • FABA-USminorGTM or Marketing PartnerFABA-US Chapter webinar collaboration featuring Sapien's biobank capabilities. Dr. Jugnu Jain presented on human patient samples and clinical data at FABA-US monthly webinar series.
  • Dr. PC Rath (Apollo Hospitals)coreStrategic or Co-development PartnerLeading cardiologist collaborating with Sapien on cardiac patient database collation and research on anti-platelet therapy optimization for PCI-stent patients.
  • Dr. PK Sahoo (Apollo Hospitals)coreStrategic or Co-development PartnerCardiologist collaborating on cardiac research and myPlatelet test utilization for personalized anti-platelet therapy in PCI-stent patients.
  • SV College of PharmacyminorStrategic or Co-development PartnerCollaboration with Dr. A Yerramilli at SV College of Pharmacy for cardiac patient research and data analysis.
  • BioNestminorStrategic or Co-development PartnerMentioned in context of partnership discussions and industry collaboration for biobanking and life sciences ecosystem development.
  • University of HyderabadminorStrategic or Co-development PartnerAcademic collaboration for glioma patient-derived 3D cultures research presented at Regional Young Investigator Meeting.

Scale indicators10 records

Recent moves7 records

Expansion highlights5 records

Sapien Biosciences competitors and assessment

Company assessment

Regional players

  • MedGenome: India-headquartered genomics and translational research company offering NGS, biomarker, and clinical genomics services. Regional peer with overlapping India-population genetics focus and pharma/biotech diagnostics service offering.
  • Strand Life Sciences: India-based genomics, bioinformatics, and clinical diagnostics provider serving hospitals and pharma. Comparable on India footprint and clinical genomics/multi-omics services, partially overlapping with Sapien's HRR NGS panel and diagnostic development work.

Emerging players

  • Reprocell (now part of Axol Bioscience): Provider of human cell-based products, iPSC-derived cells, and biobanking services for drug discovery. Overlaps with Sapien's TruCell patient-derived cell platform and drug discovery service line.

Direct peers

  • Cureline: Global human biospecimen supplier specializing in oncology and disease-state tissue with annotated clinical data. Comparable to Sapien's translational biobank services for pharma clients.
  • Indivumed: Specialized oncology biobank and translational CRO providing fresh-frozen and FFPE tumor tissue with clinical data, directly comparable to Sapien's OncoBloc and OncoPrime offerings.
  • Origene Technologies: Commercial provider of human tissue, biofluid, and cell specimens with associated data for research and diagnostic development. Direct peer in the biospecimen catalog business.
  • BioIVT: One of the world's largest commercial biospecimen providers offering ethically sourced human samples and associated data to pharma/biotech. Sapien is a direct peer in the commercial biobank/cryobank space but with a narrower oncology and India focus.

Broad incumbents

  • Brooks Life Sciences (Brooks Automation): Large established sample storage, biobanking, and life-science services provider with global footprint. Overlaps with Sapien's biobank services but operates at much broader scale and across many therapeutic areas.
  • Avantor: Global life science products and services company offering biorepository and biospecimen solutions. A broad incumbent in the lab-services and biospecimen value chain that competes for similar pharma procurement budgets.
  • Molecular Diagnostics (MolDx) Labs / Agilent Dako: Incumbent companion diagnostics and IHC/pharmDx providers such as Agilent Dako offering CDx development and IHC assays. Overlaps with Sapien's HRR NGS panel, myPlatelet, and IHC staining services in the precision medicine/CDx value chain.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Sapien Biosciences social profiles

Digital presence

Sapien Biosciences compliance and trust

Trust signal

Compliance1 record

Sapien Biosciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Sapien Biosciences leadership team

Management profile

Number of profiles

Profiles3 records

Sapien Biosciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Sapien Biosciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sapien Biosciences

What does Sapien Biosciences do?

Sapien Biosciences operates one of Asia's largest commercial biobanks with 200,000 unique patients, 2,045,000 samples, and 150 unique diseases covered, providing ethically consented, anonymized human tissue samples with associated clinical data. The company offers proprietary translational platforms (OncoBloc FFPE collections, OncoPrime patient-derived live cancer cells, MetBlock metastasis EMT model, TruCell, TruScreen) and companion diagnostic tests (myPLATELET pharmacogenomic platelet test, HRR NGS panel, BRCA1/2 testing) for pharmaceutical companies, biotech firms, academic researchers, and healthcare providers.

Is Sapien Biosciences a public or private company?

Sapien Biosciences is a private company. It is classified as corporate owned and is currently operating.

When was Sapien Biosciences founded?

Sapien Biosciences was founded in 2012. It employs 51 to 100 people.

Where is Sapien Biosciences based?

Sapien Biosciences is headquartered in Hyderabad, India, in the Asia region.

How does Sapien Biosciences make money?

Four revenue lines are on record. Biobanking Services are the primary driver. The others are diagnostic Development, drug Discovery Partnerships and myPlatelet Test.

Who are Sapien Biosciences's main competitors?

Regional players on record are MedGenome and Strand Life Sciences. Reprocell (now part of Axol Bioscience) is listed as an emerging player. Direct peers are Cureline, Indivumed, Origene Technologies and BioIVT. Broad incumbents are Brooks Life Sciences (Brooks Automation), Avantor and Molecular Diagnostics (MolDx) Labs / Agilent Dako.

Does Sapien Biosciences have an API?

No public API is recorded for Sapien Biosciences.

What industry is Sapien Biosciences in?

Sapien Biosciences's product category is Biobanking & Translational Research Services. Its primary akta.pro industry code is HLACAMAG, Biobank & Biospecimen Management LIMS, with a secondary code of HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays). Its NAICS code is 621511 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals